Antiviral vaccines with improved cellular immunogenicity
View Patent ↗The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects.
1. A nucleic acid molecule encoding a polypeptide comprising a sequence at least 99% identical to SEQ ID NO:9.
2. A vector comprising the nucleic acid molecule of claim 1 .
3. The vector of claim 2 , wherein said vector is an adenoviral vector.
4. The vector of claim 2 , wherein said vector is a pox virus vector.
5. The vector of claim 3 , wherein said vector is selected from the group consisting of adenovirus serotype 26 (Ad26), adenovirus serotype 34 (Ad34), adenovirus serotype 35 (Ad35), adenovirus serotype 48 (Ad48), and adenovirus serotype 5 HVR48 (Ad5HVR48).
6. The vector of claim 5 , wherein said vector is the Ad26 vector.
7. The vector of claim 4 , wherein the vector is a modified vaccinia virus Ankara (MVA).
8. A pharmaceutical composition comprising the vector of claim 2 and a pharmaceutically acceptable carrier, excipient, or diluent.
9. The pharmaceutical composition of claim 8 , wherein said vector is an adenoviral vector.
10. The pharmaceutical composition of claim 8 , wherein the vector is a pox virus vector.
11. The pharmaceutical composition of claim 8 , wherein said vector is selected from the group consisting of Ad26, Ad34, Ad35, Ad48, Ad5HVR48, and MVA.
12. The pharmaceutical composition of claim 8 , wherein said vector is the Ad26.
13. The pharmaceutical composition of claim 8 , wherein said vector is the MVA vector.
14. A kit comprising:
a) the pharmaceutical composition of claim 8 ;
b) instructions for use thereof; and, optionally,
c) an adjuvant.
15. A method for inducing an HIV-1 specific immune response in a mammal comprising administering to said mammal the nucleic acid of claim 1 or a vector comprising said nucleic acid.
16. The method of claim 15 , wherein said nucleic acid or said vector is in a pharmaceutical composition.
17. The method of claim 15 , wherein said vector is the Ad26 vector.
18. The method of claim 15 , wherein said vector is the MVA vector.
19. The method of claim 15 , wherein said mammal is a human.
20. A method of manufacturing the pharmaceutical composition of claim 8 , said method comprising combining a vector comprising a nucleic acid molecule encoding a polypeptide comprising a sequence at least 99% identical to SEQ ID NO:9 with a pharmaceutically acceptable carrier, excipient, or diluent.